Corporate ActionMay 18, 2026, 05:02 PM
Silence Therapeutics Enters New ATM Offering with Jefferies
AI Summary
Silence Therapeutics plc has entered into a new Open Market Sale AgreementSM with Jefferies LLC, allowing the company to offer and sell American Depositary Shares (ADSs) from time to time. This new agreement replaces and terminates a prior sales agreement from October 2021. Additionally, the company updated its disclosures, stating that following further tax analysis, it now believes it was not classified as a Passive Foreign Investment Company (PFIC) for its taxable year ended December 31, 2025.
Key Highlights
- Silence Therapeutics entered a new Open Market Sale AgreementSM with Jefferies LLC.
- The agreement allows the sale of American Depositary Shares (ADSs) up to a Maximum Program Amount.
- Each ADS represents three ordinary shares of the company.
- The new agreement replaces and terminates the prior sales agreement dated October 15, 2021.
- The company will pay Jefferies a commission of up to 3.0% of gross sales proceeds.
- Silence Therapeutics now believes it was not a Passive Foreign Investment Company (PFIC) for 2025.
Price Impact
More from SLN